Key Points
New Delhi: US-based Advent could rope in new investors into its planned combination of Suven Pharma and Cohance Life Sciences, as it looks to create a top three contract development and manufacturing organisation with a diversified shareholder base by combining the portfolio companies, according to sources in the know...
They are looking to induct new investors as part of the merger plan of Suven Pharma with Cohance..
A Suven Pharma-Cohance combination could bring together the strong client base of the former, which is a drug development partner to large global pharmaceutical companies, and the advanced active pharmaceutical ingredient (API)-lifecycle management capabilities of the latter, according to the sources...
"The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven's public shareholders and will be subject to regulatory approvals and other customary approvals," Advent said in a December 26 statement about its plan to merge Suven Pharma and Cohance...
Globally, Advent has invested over $10.4 billion across 51 companies in healthcare, as per details availed from a press statement on the Suven Pharma acquisition that was posted on its website...
